论文部分内容阅读
蛋白尿是肾脏疾病最常见的临床表现，且为肾功能进行性恶化的危险因素之一。苯那普利（洛订新）为长效，双通道排泄的血管紧张素Ⅱ转换酶抑制剂（ACFI），其降低尿蛋白的作用越来越被临床关注。我们观察了自1996年3月～1997年11月收住我科41倒蛋白尿患者，应用洛汀新联合黄芪注
Proteinuria is the most common clinical manifestations of kidney disease, and one of the risk factors for the progressive deterioration of renal function. Benazepril (lohexin) is a long-acting, dual-channel angiotensin-converting enzyme inhibitor (ACFI), and its role in reducing urinary protein is gaining more and more clinical attention. We observed 41 cases of proteinuria in our department from March 1996 to November 1997. The application of Lotensin combined with Astragalus injection